title: Substitution with doxorubicin for daunorubicin during induction for high risk pediatric acute lymphoblastic leukemia results in increased toxicity.
authors.forename: Rebecca A
authors.initials: RA
authors.lastname: Gardner
authors.forename: Blythe
authors.initials: B
authors.lastname: Thomson
authors.forename: Douglas S
authors.initials: DS
authors.lastname: Hawkins
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D003630:Daunorubicin / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects*; D057915:Drug Substitution / Q000009:adverse effects*; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy / Q000009:adverse effects; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin; D003630:Daunorubicin